Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKTX-102
- Development stage
- Preclinical
- Lead developer
- Akari Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
AKTX-102 is a novel antibody-drug conjugate (ADC) developed by Akari Therapeutics for the treatment of solid tumors. The drug employs a bispecific antibody linked to a proprietary cytotoxic payload (PH5) designed to target and disrupt DNA mismatch repair (MMR) mechanisms in tumor cells. This leads to the generation of neoepitopes—new antigens that enhance immune recognition of cancer cells. The specific cellular target of the antibody component remains undisclosed, and AKTX-102 is positioned as part of Akari's next-generation precision ADC pipeline, intended to induce highly selective cancer cell death while stimulating immune response and minimizing off-target toxicity. The compound is in the preclinical/discovery phase and has not yet reached clinical trials[1][4][5][7][14].
Beyond the preview
Go deeper on AKTX-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKTX-102.